Though preclinical and clinical evidence strongly supports GLP-1RA-mediated cardiovascular protection through multi-mechanistic pathways in diverse models, the specific effects of liraglutide on cardiovascular endpoints in TTR-related cardiac pathologies including myocardial fibrosis and heart failure remain underexplored. Here, TTR is linked to Myocardial fibrosis.